5-(3,4-二氯苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇 | 725217-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(3,4-二氯苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇
• 中文别名: 5-(3,4-二氯苯基)-4-甲基-2H-1,2,4-三唑-3-硫酮
• 英文名称: 5-(3,4-dichlorophenyl)-4-methyl-4H-1,2,4-triazole-3-thiol
• 英文别名: 3-(3,4-dichlorophenyl)-4-methyl-1H-1,2,4-triazole-5-thione
• CAS: 725217-53-8
• 化学式: C₉H₇Cl₂N₃S
• mdl: MFCD01940420
• 分子量: 260.147
• InChiKey: QCGPGOVIOSTXGK-UHFFFAOYSA-N

物化性质

• 沸点：
  336.8±52.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(3-Chloropropyl)-7-(5-methyl-isoxazol-3-yl)-2,3,4,5-tetrahydro-1H-3-benzazepine 、 5-(3,4-二氯苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇 在 sodium iodide potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 3-[3-[3-[[5-(3,4-Dichlorophenyl)-4-methyl-1,2,4-triazol-3-yl]sulfanyl]propyl]-1,2,4,5-tetrahydro-3-benzazepin-7-yl]-5-methyl-1,2-oxazole
  参考文献：
  名称：

  1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines:  A Series of Potent and Selective Dopamine D₃ Receptor Antagonists

  摘要：

  The discovery of new highly potent and selective dopamine D-3 receptor antagonists has recently permitted characterization of the role of the dopamine D-3 receptor in a wide range, of preclinical animal models. A novel series of 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines demonstrating a high level of D3 affinity and selectivity with an excellent pharmacokinetic profile is reported here. In particular, the pyrazolyl derivative 35 showed good oral bioavailability and brain penetration associated with high potency and selectivity in vitro. In vivo characterization of 35 confirmed that this compound blocks the expression of nicotine- and cocaine-conditioned place preference in the rat, prevents nicotine-triggered reinstatement of nicotine- seeking behavior in the rat, reduces oral operant alcohol self- administration in the mouse, increases extracellular levels of acetylcholine in the rat medial prefrontal cortex, and potentiates the amplitude of the relative cerebral blood volume response to d-amphetamine in a regionally specific manner in the rat brain.

  DOI：

  10.1021/jm0705612
• 作为产物：
  描述：

  3,4-二氯苯甲酸 、 4-甲基氨基硫脲 在 1-丙基磷酸酐 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 生成 5-(3,4-二氯苯基)-4-甲基-4H-1,2,4-噻唑-3-硫醇
  参考文献：
  名称：

  [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
  [FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE

  摘要：

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。

  公开号：

  WO2020257487A1

文献信息

• Glycolate oxidase inhibitors for the treatment of disease
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US11384055B2

  公开（公告）日：2022-07-12

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述的是化合物、制造此类化合物的方法、含有此类化合物的药物组合物和药剂，以及使用此类化合物治疗或预防与乙醛酸氧化酶（GO）相关的疾病或紊乱的方法。此类疾病或紊乱包括，例如，与产生过量草酸盐有关的乙醛酸代谢紊乱，包括原发性高草酸尿症。
• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2019133770A3

  公开（公告）日：2019-08-15
• GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US20210171474A1

  公开（公告）日：2021-06-10

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines:  A Series of Potent and Selective Dopamine D₃ Receptor Antagonists
  作者：Fabrizio Micheli、Giorgio Bonanomi、Frank E. Blaney、Simone Braggio、Anna Maria Capelli、Anna Checchia、Ornella Curcuruto、Federica Damiani、Romano Di Fabio、Daniele Donati、Gabriella Gentile、Andy Gribble、Dieter Hamprecht、Giovanna Tedesco、Silvia Terreni、Luca Tarsi、Andrew Lightfoot、Geoff Stemp、Gregor MacDonald、Alex Smith、Michela Pecoraro、Marcella Petrone、Ornella Perini、Jacqui Piner、Tino Rossi、Angela Worby、Maria Pilla、Enzo Valerio、Cristiana Griffante、Manolo Mugnaini、Martyn Wood、Claire Scott、Michela Andreoli、Laurent Lacroix、Adam Schwarz、Alessandro Gozzi、Angelo Bifone、Charles R. Ashby,、Jim J. Hagan、Christian Heidbreder

  DOI：10.1021/jm0705612

  日期：2007.10.1

  The discovery of new highly potent and selective dopamine D-3 receptor antagonists has recently permitted characterization of the role of the dopamine D-3 receptor in a wide range, of preclinical animal models. A novel series of 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines demonstrating a high level of D3 affinity and selectivity with an excellent pharmacokinetic profile is reported here. In particular, the pyrazolyl derivative 35 showed good oral bioavailability and brain penetration associated with high potency and selectivity in vitro. In vivo characterization of 35 confirmed that this compound blocks the expression of nicotine- and cocaine-conditioned place preference in the rat, prevents nicotine-triggered reinstatement of nicotine- seeking behavior in the rat, reduces oral operant alcohol self- administration in the mouse, increases extracellular levels of acetylcholine in the rat medial prefrontal cortex, and potentiates the amplitude of the relative cerebral blood volume response to d-amphetamine in a regionally specific manner in the rat brain.